Phalguni Deswal
LightNews LightNews
phalguniddw.bsky.social
Phalguni Deswal
@phalguniddw.bsky.social
19 followers 11 following 220 posts
Editor - Drug and Device World
Posts Replies Media Videos
phalguniddw.bsky.social
Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds, aiming to prevent amputations. Read more for company's pipeline and future plans
#MedTech #WoundCare #FDA #Diabetes #Innovation #Interview #News
Rapid Nexus charts a new path for chronic wounds
Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds and the company’s pipeline.
druganddeviceworld.com
December 15, 2025 at 8:55 AM
phalguniddw.bsky.social
New data from Agendia's FLEX study at #SABCS2025 shows genomic signatures like MammaPrint can guide chemo choices & identify benefit in elderly patients.
#news #breastcancer #precisionmedicine #realworldevidence
SABCS25: Agendia’s genomic testing guides breast cancer care 
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.
druganddeviceworld.com
December 12, 2025 at 8:09 PM
phalguniddw.bsky.social
HeartBeam receives FDA clearance for the first cable-free, at-home 12-lead ECG. This breakthrough allows for clinical-grade heart rhythm assessment anytime, anywhere. A major leap for remote cardiac care.
#New #HeartBeam #FDA #MedTech #Cardiology #DigitalHealth
HeartBeam’s stock shows strong pulse after FDA clearance
A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.
druganddeviceworld.com
December 12, 2025 at 7:29 PM
phalguniddw.bsky.social
AC Immune's Phase 2 vaccine for Parkinson’s shows first-ever signs of potentially slowing disease progression. 100% 100% responder rate for immunogenicity & stabilized biomarkers signal a promising step forward.
#News #Parkinsons #Biotech #ClinicalTrial #Neurodegenerative #ACI7104
AC Immune’s stock rises with positive Phase II data
Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson's treatment.
druganddeviceworld.com
December 12, 2025 at 7:06 PM
phalguniddw.bsky.social
VUGENE teams up with CRO Inotiv to accelerate AI-driven drug discovery through advanced multi-omics analysis. A key move into the pharmaceutical services market.

#News #AI #DrugDiscovery #MultiOmics #Bioinformatics #CRO #Biotech
VUGENE partners with Inotiv to power AI-driven drug discovery
Lithuanian bioinformatics firm launches into pharmaceutical services via a strategic CRO collaboration aimed at accelerating multi-omics analysis.
druganddeviceworld.com
December 12, 2025 at 6:22 PM
phalguniddw.bsky.social
Sanofi’s #ASH25 data highlight leadership in rare blood diseases, from multi-immune modulation with #BTKinhibitor Wayrilz to long-term hemophilia care with ALTUVIIIO. Transforming patient lives through science.
#News #Interview #RareDisease #Hemophilia #Immunoscience
Sanofi’s ASH 2025: Redefining rare blood disorder care
Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.
druganddeviceworld.com
December 10, 2025 at 11:57 AM
phalguniddw.bsky.social
Vyome shares rise on positive Phase 2 data for its wound care gel VT-1953, showing significant reduction in odor & pain. Pivotal study targeted for 2026.
#News #Biotech #ClinicalTrial #Healthcare #WoundCare
Vyome’s stock rises on positive Phase II data for wound care drug
Vyome's VT-1953 gel significantly reduced odor and pain in malignant fungating wounds, prompting plans for a pivotal Phase III study.
druganddeviceworld.com
December 9, 2025 at 11:19 AM
phalguniddw.bsky.social
Tessera Therapeutics' Gene Writing platform hits new preclinical milestones. Data shows edited stem cells exceed curative thresholds for sickle cell disease & successful in vivo generation of functional CAR-T cells.
#News #GeneWriting #SickleCellDisease #CAR_T #ASH2025 #Biotech
ASH25: Tessera’s gene writing hits curative thresholds in sickle cell
New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.
druganddeviceworld.com
December 9, 2025 at 10:17 AM
phalguniddw.bsky.social
BREAKING: Dicot Pharma unveils how LIB-01, a new class of ED drug, works. It targets the brain's melanocortin system for a sustained effect, even in non-responders. Phase 2a data shows benefits last 8+ weeks.

#News #EDtreatment #menshealth #clinicaltrial #ErectileDysfunction
Dicot Pharma unlocks sustained ED effect with LIB-01
Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.
druganddeviceworld.com
December 8, 2025 at 7:41 PM
phalguniddw.bsky.social
New data reveals ATIVA's RECELL spray-on skin treatment reduces burn patient hospital stays by 5.6 days, saving ~$42k per case. The minimally invasive approach means less pain, faster healing, and better cosmetic outcomes.
#BurnCare #News #MedicalInnovation #PatientOutcomes #HealthcareEfficiency
AVITA’s spray on skin cells slashes pain and hospital stays
Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.
druganddeviceworld.com
December 8, 2025 at 9:35 AM
phalguniddw.bsky.social
Iolyx Therapeutics partners with Laboratoires Théa in a deal worth up to $280M to advance ILYX-002, a novel eye drop for autoimmune dry eye. Phase 2 data showed early, sustained improvement.
#news #biotech #ophthalmology #dryeye #autoimmune #collaboration
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
druganddeviceworld.com
December 5, 2025 at 11:10 AM
phalguniddw.bsky.social
Shocked by the lack of funding in women's health, BioMed X launches XFem Labs with Gates Foundation to bridge the R&D gap. Their first mission: non-hormonal contraception.
#News #WomensHealth #HealthEquity #Biotech #GatesFoundation #Innovation
The $1 trillion blind spot: Bridging the gap in women’s health
Dr. Christian Tidona, founder and CEO of BioMed X, on why women's health is critically underfunded and how a new initiative aims to change that.
druganddeviceworld.com
December 5, 2025 at 10:37 AM
phalguniddw.bsky.social
Pharvaris announces positive Phase 3 results for oral deucrictibant in HAE. The drug showed rapid symptom relief in 1.28 hrs & was well-tolerated. Regulatory filings are planned for H1 2026.

#News #Pharvaris #deucrictibant #HAE #RareDisease #Phase3 #Biotech
Pharvaris stock rises following positive Phase III topline data
The company’s oral drug deucrictibant significantly sped up symptom relief in the Phase III trial, positioning it for 2026 regulatory filings.
druganddeviceworld.com
December 5, 2025 at 10:21 AM
phalguniddw.bsky.social
Brainomix's AI imaging (Brainomix 360) doubled endovascular thrombectomy rates & cut transfer delays by 64 mins across 107 NHS hospitals.
#News #Study #Stroke #AI #DigitalHealth #Thrombectomy #NHS
Brainomix’s AI stroke tool doubles life-saving surgery rates in NHS study
The study indicated that Brainomix 360 Stroke led to a 100% increase in endovascular thrombectomy rates and sped up patient transfers across 107 UK hospitals.
druganddeviceworld.com
December 5, 2025 at 9:49 AM
phalguniddw.bsky.social
New hope against snakebites! 🐍 COVID-era mRNA tech could create a faster, broader treatment to prevent death & disability. A game-changer for rural communities.
#mRNA #Snakebite #GlobalHealth #Biotech #MedicalInnovation
mRNA technology set to revolutionize snakebite treatment
UK researcher Prof. Vaiyapuri discusses how Covid vaccine technology could soon neutralize deadly snake venom, preventing death and disability for millions.
druganddeviceworld.com
December 3, 2025 at 9:34 AM
phalguniddw.bsky.social
Santersus AG raises Series A funding led by Norcliffe Capital. Also, a new strategic collaboration with Terumo aims to advance NucleoCapture, a breakthrough blood purification device, into pivotal trials for sepsis.

#News #Biotech #MedTech #Sepsis #Funding #Innovation #SeriesA
Santersus secures funding to advance blood purification tech
Swiss biotech raises Series A financing to drive pivotal trials for its blood purification technology for sepsis and lupus therapy.
druganddeviceworld.com
December 2, 2025 at 10:59 AM
phalguniddw.bsky.social
Regeneron Pharmaceuticals and Tessera Therapeutics sign a $275 million deal to develop TSRA-196, a potential one-time #GeneEditing therapy for Alpha-1 Antitrypsin Deficiency.

#News #deal #partneship #GeneTherapy #AATD #Pharma
Regeneron and Tessera ink $275 mil pact for gene editing therapy
The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.
druganddeviceworld.com
December 2, 2025 at 10:16 AM
phalguniddw.bsky.social
Salignostics launches SaliStick, the world's first saliva pregnancy test, across Australia in partnership with Coles.

#News #SaliStick #SalivaTest #HealthTech #WomensHealth #Salignostics
Saliva pregnancy test hits Australian shelves
Salignostics partners with Coles Supply to launch its innovative SaliStick saliva-based pregnancy test across Australia.
druganddeviceworld.com
November 27, 2025 at 6:07 PM
phalguniddw.bsky.social
Big news in India! Biocomposites' Stimulan Rapid Cure now has expanded approval to be mixed with more antibiotics & the world's first approval for antifungals, helping surgeons fight surgical infections. 🦠⚔️

#News #STIMULAN #Biocomposites #MedTech #SurgicalInfections #Ortho #India #AMR
Biocomposites gains wider antimicrobial approval in India
The company’s Stimulan Rapid Cure can now be mixed with more antibiotics and antifungals in India to combat surgical infections.
druganddeviceworld.com
November 27, 2025 at 5:46 PM
phalguniddw.bsky.social
Bracco, Limula, and University of Fribourg partner to revolutionize cell therapy manufacturing. Their novel approach uses gentle buoyancy-based tech to improve product quality and patient outcomes.
#News #Partnership #CellTherapy #Biotech #Innovation #CAR-T #Manufacturing
New Swiss alliance to improve cell therapy manufacturing
The industry-academia partnership of Bracco Imaging, Limula, and the University of Fribourg aims to revolutionize how life-saving 'living drugs' are made.
druganddeviceworld.com
November 26, 2025 at 10:59 AM
phalguniddw.bsky.social
RapidAI gains FDA clearance for 5 new clinical AI modules, expanding its platform to advance stroke, neurology, and vascular care.

#News #AI #HealthTech #FDA #Radiology #Stroke #Innovation #FDAclearance #AIimaging
RapidAI wins FDA nod for five new AI tools
RapidAI bolsters its clinical AI platform with new FDA-cleared modules designed to enhance neurology, vascular, and radiology care.
druganddeviceworld.com
November 26, 2025 at 10:23 AM
phalguniddw.bsky.social
NanoTemper's acquisition of Envue & launch of Dianthus α let researchers see single molecules & slow kinetics in real time. Transforming early drug discovery.

#News #Interivew #DrugDiscovery #Biotech #Innovation #Therapeutics #Manufacturing
NanoTemper’s vision: Seeing molecules in real time
The company's CEO talks about the new tech that reveals hidden molecular dynamics, and how the recent acquisition fits into the company’s overall vision.
druganddeviceworld.com
November 26, 2025 at 9:54 AM
phalguniddw.bsky.social
Circio's new circVec 4.0 boosts gene expression by 50%. New data shows stronger heart performance and 4x higher brain expression, opening new CNS therapy avenues.

#News #Biotech #GeneTherapy #RNA #CNS #Opthalmology
Circio bolsters data for circVec circular RNA expression platform
New data shows enhanced performance in heart and brain tissues, broadening the platform's therapeutic potential and boosting gene expression by 50%.
druganddeviceworld.com
November 25, 2025 at 10:20 AM
phalguniddw.bsky.social
Levron Medical exits stealth with new CRPA tech aimed at transforming heart failure treatment. Backed by new funding and early clinical results, the company is moving into validation at Sheba Medical Center.
#News #MedTech #Innovation #HeartFailure #Healthcare #ClinicalResearch #IsraelTech
Levron Medical emerges with new approach to treating heart failure
Following first-in-human results and new funding, the company prepares for a clinical study at Sheba Medical Center.
druganddeviceworld.com
November 25, 2025 at 9:54 AM
phalguniddw.bsky.social
Sorcero raised $42.5 million in Series B funding to scale its AI-powered life sciences platform.

#News #AI #Pharma #LifeSciences #HealthcareInnovation #Funding #MedTech
Sorcero raises $42.5 million for AI adoption in life sciences
The company plans to use the new investment to scale its AI platform and expand applications across global pharmaceutical and medical device sectors.
druganddeviceworld.com
November 24, 2025 at 8:08 PM